Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several statements align with the provided label excerpt (indication for anogenital warts, twice-daily for 3 days then 4 days off up to 4 cycles, contraindication for hypersensitivity, cutaneous-only/avoid eyes). However, multiple statements are unsupported or conflict with the label excerpt, particularly mechanism of action and several safety/product-use assertions not present in the supplied label text.
Category Scores
Accurate Statements
Podofilox topical solution is a prescription medication.
Not supported by the provided label excerpts.
Podofilox topical solution is used to treat external genital warts.
Supported indirectly: Condylox Gel 0.5% indicated for topical treatment of anogenital warts (external genital warts and perianal warts).
Podofilox topical solution is available in a 0.5% concentration.
Supported by the provided excerpt referring to Condylox Gel 0.5% and 0.5% podofilox solution.
The cycle of application for three to four consecutive days followed by a four-day treatment-free interval may be repeated up to four times if warts remain.
Supported: Apply twice daily for 3 consecutive days, discontinue for 4 consecutive days; one-week cycle may be repeated until no visible wart tissue or for a maximum of four cycles.
Common side effects of Podofilox topical solution include local irritation at the application site, such as burning, stinging, itching, and redness.
Partially supported: burning and itching listed; stinging and erythema listed as other local adverse events.
Potential side effects of Podofilox topical solution include pain, inflammation, or small sores on the treated area.
Partially supported: inflammation and pain are listed; erosion is listed (a form of tissue damage/lesion) as an adverse reaction category.
Severe skin reactions are rare but possible with Podofilox topical solution.
Supported in direction: severe reactions occurred (table includes severe percentages); severity described as predominantly mild/moderate.
Unsupported Statements
Podofilox topical solution contains podophyllum resin.
The provided label excerpt does not state formulation components for podofilox solution.
Podophyllum resin is a compound derived from the Mayapple plant.
Not stated in the provided label excerpt.
Podophyllum resin is a cytotoxic agent.
Not stated in the provided label excerpt.
Podofilox topical solution works by inhibiting cell growth in the warts.
Not supported by the provided mechanism section. The label states results in necrosis of visible wart tissue and the exact mechanism is unknown.
Podofilox topical solution causes warts to break down and slough off over time.
The provided mechanism states necrosis of visible wart tissue, but the specific phrasing of 'slough off over time' is not directly stated in the excerpt.
Podofilox topical solution is applied directly to the warts.
While application to warts is described for Condylox Gel (applied to the warts with applicator tip or finger), the provided excerpts do not explicitly confirm this statement for 'Podofilox topical solution' as a distinct product form; label excerpt is for Condylox Gel 0.5%.
Podofilox topical solution is typically applied twice a day for three to four consecutive days.
The label excerpt specifies 3 consecutive days, not 'three to four consecutive days'.
After three to four consecutive days, Podofilox topical solution use includes a four-day treatment-free interval.
Label specifies 3 consecutive days followed by 4 consecutive days off; 'three to four consecutive days' is not supported.
The cycle of application for three to four consecutive days followed by a four-day treatment-free interval may be repeated up to four times if warts remain.
The repetition concept is supported, but the 'three to four consecutive days' part is not.
Podofilox topical solution should not be used by individuals with weakened immune systems.
Not stated in provided label excerpt sections.
Podofilox topical solution should not be used by pregnant or breastfeeding women.
Label excerpt does not contraindicate pregnancy or nursing; it provides pregnancy caution (use only if benefit justifies risk) and nursing decision-making.
Podofilox topical solution should not be used in individuals with open sores or broken skin in the genital area.
Not stated in provided label excerpt.
Podofilox topical solution is not suitable for everyone.
This is a vague generalization; not directly supported by provided label excerpts.
Podofilox topical solution is a prescription medication.
Not stated in provided label excerpt.
Contradictions
Low
AI Statement
Podofilox topical solution works by inhibiting cell growth in the warts.
Label Reference
Mechanism of Action section states: 'Treatment ... results in necrosis of visible wart tissue. The exact mechanism of action is unknown.'
Low
AI Statement
Podofilox topical solution should not be used by pregnant or breastfeeding women.
Label Reference
Pregnancy section: 'Condylox Gel 0.5% should be used during pregnancy only if the potential benefit justifies the potential risk.' Nursing Mothers: decision to discontinue nursing or drug based on importance.
Low
AI Statement
Podofilox topical solution is typically applied twice a day for three to four consecutive days.
Label Reference
DOSAGE AND ADMINISTRATION: 'Apply twice daily for 3 consecutive days, then discontinue for 4 consecutive days.'
Important Omissions
Important administration limits from the label excerpt are not included in the AI statements: limit treatment to 10 cm^2 or less and no more than 0.5 g of gel per day; minimize application on surrounding normal tissue; allow gel to dry before returning opposing skin surfaces; wash hands before and after each application; discontinue if incomplete response after four cycles.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response includes several statements not supported by the provided label excerpt (e.g., pregnancy/breastfeeding as 'should not be used') and some dosing imprecision (3 to 4 days instead of 3). It also omits key administration limits (area and maximum daily amount) and other label-specific safety instructions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple safety-related statements (pregnancy/nursing) contradict the provided label excerpt and several dosing/administration details are inaccurate or omitted (e.g., 'three to four consecutive days', lack of area/maximum daily dose limits).
Suggested Improvement
Align dosing to exactly '3 consecutive days then 4 days off' and explicitly include label administration limits (≤10 cm^2 and ≤0.5 g/day), and replace contraindictory pregnancy/nursing statements with the label’s risk/benefit language. Remove unsupported formulation and mechanism claims not present in the provided label excerpt.